BMI Eligibility Checker for GLP-1
Check if your BMI meets the criteria for GLP-1 weight loss medication.
Disclaimer: This tool provides a preliminary check only. Final eligibility is determined by a licensed healthcare provider based on your complete medical history.
Check Your BMI Eligibility
GLP-1 Eligibility Criteria
- BMI 30 or higher: Qualifies for GLP-1 weight loss medication (no comorbidity required)
- BMI 27-29.9 with comorbidity: Qualifies if you have type 2 diabetes, hypertension, dyslipidemia, sleep apnea, or other weight-related conditions
- BMI below 27: Does not typically meet standard eligibility criteria for weight loss indication
Frequently Asked Questions
What BMI qualifies for GLP-1 medication?
FDA guidelines indicate GLP-1 weight loss medications for adults with BMI 30+ (obese), or BMI 27+ (overweight) with at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea.
Is BMI the only factor for eligibility?
No. While BMI is the primary screening criterion, providers also consider your overall health, medical history, current medications, and contraindications. Some patients with BMI below 27 may benefit from treatment for specific medical conditions like type 2 diabetes.
What are weight-related comorbidities?
Common comorbidities that qualify you at BMI 27+ include: type 2 diabetes or prediabetes, high blood pressure, high cholesterol or triglycerides, obstructive sleep apnea, PCOS, fatty liver disease, and osteoarthritis.
Is BMI an accurate measure of health?
BMI has limitations: it does not distinguish between muscle and fat, does not account for body composition, and may underestimate or overestimate health risk for certain populations. However, it remains the standard clinical screening tool for GLP-1 eligibility.
Start Your Consultation
A Trimi clinician can evaluate your full health picture and determine if GLP-1 treatment is right for you.
Get Started TodayMore on Calculators & Tools
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).